CD274 and neoplasm: Compared with our anti-PD-L1 primary resistance tumor model, innate immune agonists such as TLR agonists, the Sting pathway, and oncolytic viruses might enhance the anti-tumor effect treated with anti-PD-L1 Ab in PD-L1 sensitive tumor models.